We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Doximity (DOCS) Stock Moves -0.16%: What You Should Know
Read MoreHide Full Article
Doximity (DOCS - Free Report) closed the most recent trading day at $55.48, moving -0.16% from the previous trading session. This change was narrower than the S&P 500's daily loss of 1.11%. Elsewhere, the Dow lost 0.42%, while the tech-heavy Nasdaq lost 1.89%.
Prior to today's trading, shares of the medical social networking site had gained 3.23% over the past month. This has outpaced the Medical sector's loss of 6.22% and the S&P 500's loss of 1.7% in that time.
The investment community will be closely monitoring the performance of Doximity in its forthcoming earnings report. In that report, analysts expect Doximity to post earnings of $0.33 per share. This would mark year-over-year growth of 13.79%. Meanwhile, the latest consensus estimate predicts the revenue to be $152.44 million, indicating a 12.69% increase compared to the same quarter of the previous year.
In terms of the entire fiscal year, the Zacks Consensus Estimates predict earnings of $1.14 per share and a revenue of $539.15 million, indicating changes of +20% and +13.4%, respectively, from the former year.
Investors should also pay attention to any latest changes in analyst estimates for Doximity. Such recent modifications usually signify the changing landscape of near-term business trends. Therefore, positive revisions in estimates convey analysts' confidence in the company's business performance and profit potential.
Our research shows that these estimate changes are directly correlated with near-term stock prices. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. The Zacks Consensus EPS estimate remained stagnant within the past month. Doximity is currently sporting a Zacks Rank of #1 (Strong Buy).
Investors should also note Doximity's current valuation metrics, including its Forward P/E ratio of 48.8. For comparison, its industry has an average Forward P/E of 17.08, which means Doximity is trading at a premium to the group.
We can also see that DOCS currently has a PEG ratio of 3.4. Comparable to the widely accepted P/E ratio, the PEG ratio also accounts for the company's projected earnings growth. By the end of yesterday's trading, the Medical Services industry had an average PEG ratio of 1.37.
The Medical Services industry is part of the Medical sector. This industry, currently bearing a Zacks Industry Rank of 150, finds itself in the bottom 41% echelons of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics, and much more, on Zacks.com.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Doximity (DOCS) Stock Moves -0.16%: What You Should Know
Doximity (DOCS - Free Report) closed the most recent trading day at $55.48, moving -0.16% from the previous trading session. This change was narrower than the S&P 500's daily loss of 1.11%. Elsewhere, the Dow lost 0.42%, while the tech-heavy Nasdaq lost 1.89%.
Prior to today's trading, shares of the medical social networking site had gained 3.23% over the past month. This has outpaced the Medical sector's loss of 6.22% and the S&P 500's loss of 1.7% in that time.
The investment community will be closely monitoring the performance of Doximity in its forthcoming earnings report. In that report, analysts expect Doximity to post earnings of $0.33 per share. This would mark year-over-year growth of 13.79%. Meanwhile, the latest consensus estimate predicts the revenue to be $152.44 million, indicating a 12.69% increase compared to the same quarter of the previous year.
In terms of the entire fiscal year, the Zacks Consensus Estimates predict earnings of $1.14 per share and a revenue of $539.15 million, indicating changes of +20% and +13.4%, respectively, from the former year.
Investors should also pay attention to any latest changes in analyst estimates for Doximity. Such recent modifications usually signify the changing landscape of near-term business trends. Therefore, positive revisions in estimates convey analysts' confidence in the company's business performance and profit potential.
Our research shows that these estimate changes are directly correlated with near-term stock prices. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. The Zacks Consensus EPS estimate remained stagnant within the past month. Doximity is currently sporting a Zacks Rank of #1 (Strong Buy).
Investors should also note Doximity's current valuation metrics, including its Forward P/E ratio of 48.8. For comparison, its industry has an average Forward P/E of 17.08, which means Doximity is trading at a premium to the group.
We can also see that DOCS currently has a PEG ratio of 3.4. Comparable to the widely accepted P/E ratio, the PEG ratio also accounts for the company's projected earnings growth. By the end of yesterday's trading, the Medical Services industry had an average PEG ratio of 1.37.
The Medical Services industry is part of the Medical sector. This industry, currently bearing a Zacks Industry Rank of 150, finds itself in the bottom 41% echelons of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics, and much more, on Zacks.com.